The Rna Is Antisense Patents (Class 800/286)
  • Patent number: 11926833
    Abstract: The present disclosure relates to a transgenic plant cell comprising polynucleotide sequences encoding glycolate dehydrogenase, malate synthase, and an inhibitory polynucleotide targeting an endogenous glycolate transporter Plgg1, wherein expression of endogenous glycolate transporter Plgg1 in the transgenic plant cell is about 20% to 80% of expression of endogenous glycolate transporter Plgg1 in a plant cell that is not transformed with an inhibitory polynucleotide targeting an endogenous glycolate transporter Plgg1. Also disclosed are transgenic plants, transgenic plant cultures, and methods for increasing photosynthesis efficiency in plants. The disclosed methods enhance biomass productivity and reduce the negative impact of photorespiration and introduction of transgenic constructs on plant growth.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: March 12, 2024
    Assignee: LIVING CARBON PBC
    Inventors: Madeline Hall, Li-Wei Chiu, Rebecca Dewhirst, Jacob Hoyle, Patrick Mellor, Karli Rasmussen, Yumin Tao
  • Patent number: 11732266
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 22, 2023
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul, Yuan Cheng
  • Patent number: 11485975
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Peter Hagedorn, Marianne L. Jensen, Lukasz Kielpinski, Amy Easton, Benny Chih
  • Patent number: 11377664
    Abstract: A formulation is provided for application to a host plant to reduce, inhibit or impair one or more of growth and development of the host plant. A method of inhibiting growth plant growth and development is also provided as a means of controlling weedy species. The method comprises: selecting a suitable gene for growth suppression in a target plant; identifying an at least one target site accessible to base pairing in the suitable gene; identifying an at least one divergent site in the at least one target site; designing a construct complementary to the at least one divergent site; adding an at least one RNAi inducer to the construct; and delivering the construct to the target plant.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 5, 2022
    Assignee: Terramera, Inc.
    Inventors: Chris Tuttle, Layne Woodfin
  • Patent number: 11359205
    Abstract: A genetically modified fruit-producing plant, said plant having sufficiently reduced total Polyphenol Oxidase (PPO) activity relative to a wild type of said plant to reduce browning in the fruit of said plant relative to said wild type, wherein the reduced total PPO activity results from a reduction in activity of at least two PPO isoenzymes in said plant relative to said wild type, or a cell, seed, seedling, part, tissue, cell, fruit or progeny of said plant.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 14, 2022
    Assignee: OKANAGAN SPECIALITY FRUITS INC.
    Inventors: John Armstrong, William David Lane
  • Patent number: 11304440
    Abstract: This disclosure provides tobacco plants containing a PMT RNAi and tobacco plants having a mutation in PMT, and methods of making and using such plants.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 19, 2022
    Assignee: Altria Client Services LLC
    Inventors: Chengalrayan Kudithipudi, Alec J. Hayes, Marcos Fernando de Godoy Lusso, Jerry Whit Morris
  • Patent number: 11279942
    Abstract: Compositions and methods for improving plant growth are provided herein. The maize RbcS7A promoter is provided which is a developmentally regulated promoter. Polynucleotides encoding ferredoxin-thioredoxin reductase proteins, polypeptides encompassing ferredoxin-thioredoxin reductase proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 22, 2022
    Assignee: Benson Hill, Inc.
    Inventor: Matthew Begemann
  • Patent number: 11229663
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the serum amyloid P component (APCS) gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of an APCS gene and to treat subjects having an APCS-associated disease, e.g., amyloidosis, Alzheimer's disease or coronary atherosclerotic heart disease.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: January 25, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Gregory Hinkle
  • Patent number: 11174493
    Abstract: The present invention is directed to seedless fruit producing plants. The present invention also comprises methods for production of said plants and the use of nucleic acids encoding cyclin SDS like proteins for the production of seedless fruits.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 16, 2021
    Assignee: NUNHEMS B.V.
    Inventors: Alberto Sirizzotti, Richard Bernard Berentsen, Hendrik Willem Vriezen
  • Patent number: 11066670
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 20, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • Patent number: 11028391
    Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: June 8, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: David Sharp, Brian O'Rourke
  • Patent number: 10982219
    Abstract: Altered guayule that produce more rubber than the amount of rubber produced by non-altered guayule are provided. The alterations may include (i) a reduction in amount of functional PaAos produced by the altered guayule, (ii) an increase in amount of a transcription factor produced by the altered guayule, (iii) an increase in amount of salicylic acid within the altered guayule, (iv) exposure of the altered guayule to cold temperature, and (v) a combination thereof. Methods of producing the altered guayule and methods of increasing the amount of rubber produced by a guayule are also provided.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: April 20, 2021
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Colleen M. McMahan, Maureen C. Whalen, Dante Placido, Niu Dong
  • Patent number: 10898507
    Abstract: Disclosed are double stranded RNA molecules that are toxic to coleopteran insects. In particular, interfering RNA molecules capable of interfering with pest target genes and that are toxic to the target pest are provided. Further, methods of making and using the interfering RNA, for example in transgenic plants or as the active ingredient in a composition, to confer protection from insect damage are disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: January 26, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Kevin V. Donohue, Yann Naudet, Pascale Feldmann, Lies Degrave, Isabelle Maillet
  • Patent number: 10865415
    Abstract: Provided are a dsRNA construct of an orphan G-protein-coupled receptor GPR160 gene related to prostate cancer and the use thereof, wherein the dsRNA construct of the GPR160 gene and a composition thereof can prevent or treat prostate cancer.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 15, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Caihong Zhou, Xinchuan Dai, Mingwei Wang
  • Patent number: 10815491
    Abstract: Transcription regulatory elements, namely promoter and terminator sequences, obtained from Sorghum bicolor that drive RNA transcription predominately in root hair cells are described, as well as cassettes, expression vectors, and genetically modified plants containing these transcription regulatory elements. The genetically modified plants can be gymnosperms, dicots, or monocots. Methods of directing transcription of a heterologous polynucleotide under control of these transcription regulatory elements in a genetically modified plant's root hair cells are also provided.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 27, 2020
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Scott R. Baerson, Zhiqiang Pan, James J Polashock
  • Patent number: 10550162
    Abstract: Compositions and methods for genetically modifying the production levels of nicotine and other alkaloids in plants are provided.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: February 4, 2020
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Michael Paul Timko, Paul J Rushton, Marta Tatiana Bokowiec
  • Patent number: 10519448
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonecleotides and their use in treating diseases and disorders associated with the expression of BDNF.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: December 31, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Patent number: 10519442
    Abstract: The present invention relates to compositions comprising TWIST signaling inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 31, 2019
    Assignee: City of Hope
    Inventors: Carlotta A. Glackin, John Rossi, Jeffrey I. Zink, Fuyuhiko Tamanoi, Cai M. Roberts, James Finlay
  • Patent number: 10415039
    Abstract: The present invention provides, among other things, oligonucleotide modulators of human 5?-HT2C receptor (HTR2C) and improved methods and composition for treating HTR2C-related diseases, disorders or conditions based on such modulators. In particular, oligonucleotides modulators according to the invention target specific regions in the Exon V/Intron V junction of the human HTR2C pre-mRNA and drive expression of HTR2C Vb splice isoform, leading to increased generation of non-edited strong HTR2C receptor and enhanced serotonin receptor activity.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: September 17, 2019
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Stefan Stamm, Manli Shen, Serene Josiah
  • Patent number: 10370655
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 6, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 10273481
    Abstract: Provided is an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia, and particularly, provided are a method of a tandem expression for siRNA of BTK, and an siRNA in tandem expression and uses thereof in treating chronic lymphocytic leukemia.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: April 30, 2019
    Assignee: Jiangsu Mircromedmark Biotech Co., LTD.
    Inventors: Chenyu Zhang, Ke Zeng, Hongwei Gu, Xueliang Wang
  • Patent number: 9902956
    Abstract: A method of improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant is provided by expressing within the plant an exogenous polynucleotide encoding a polypeptide having an amino acid sequence at least 80% homologous to SEQ ID NOs: 687-981, 992-1248, 1281-1310, 1389-1391, and 2806-3081. Also provided is a method of improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plan by expressing within the plant an exogenous polynucleotide which downregulates an activity or expression of a polypeptide having an amino acid sequence at least 80% homologous to SEQ ID NOs: 311-514, 2007-2436, 1311-1320, 982-991, 1249-1280, 1321-1388. Transgenic plants and constructs are provided as well.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: February 27, 2018
    Assignee: A.B. Seeds Ltd.
    Inventors: Rudy Maor, Iris Nesher, Orly Noivirt-Brik
  • Patent number: 9879256
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense polynucleotides of Hepatocyte Growth Factor (HGF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HGF.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 30, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 9593332
    Abstract: The present invention relates to compositions and methods for targeting immunoglobulins and immunoglobulin-producing plasma cells. In particular, the present invention provides nucleic acid based compounds for targeting immunoglobulins for research, screening, and therapeutic applications.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 14, 2017
    Assignee: TUFTS MEDICAL CENTER
    Inventors: Raymond Comenzo, Ping Zhou, Xun Ma
  • Patent number: 9567588
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 14, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Patent number: 9528119
    Abstract: Disclosed herein are transgenic cells expressing a heterologous nucleic acid encoding a prephenate dehydrogenase (PDH) protein, a heterologous nucleic acid encoding a homogentisate solanesyl transferase (HST) protein, a heterologous nucleic acid encoding a deoxyxylulose phosphate synthase (DXS) protein, or a combination of two or more thereof. In particular examples, the disclosed transgenic cells have increased plastoquinone levels. Also disclosed are methods of increasing cell growth rates or production of biomass by cultivating transgenic cells expressing a heterologous nucleic acid encoding a PDH protein, a heterologous nucleic acid encoding an HST protein, a heterologous nucleic acid encoding a DXS protein, or a combination of two or more thereof under conditions sufficient to produce cell growth or biomass.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: December 27, 2016
    Assignee: LOS ALAMOS NATIONAL SECURITY, LLC
    Inventors: Richard T. Sayre, Sowmya Subramanian, Edgar Cahoon
  • Patent number: 9518270
    Abstract: The present invention relates to plants of the Compositae family exhibiting a reversible genic male sterility trait, characterized in that the genic male sterility may be caused by a reduction or complete absence of endogenous jasmonic acid production, resulting from interference with one or more target genes involved in endogenous jasmonic acid production, selected from the group consisting of lipoxygenase, allene oxide synthase, allene oxide cyclase and 12-oxo-phytodienoic acid-10,11-reductase, or their functional homologs.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: December 13, 2016
    Assignee: RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V.
    Inventors: Cornelis Maria Petrus Van Dun, Beatrice Ingrid Lindhout, Johannes Wilhelmus Schut
  • Patent number: 9422552
    Abstract: The present invention pertains to the use of at least one abasic modification within the first 8 nucleotide positions of the 5? region of the antisense strand of a small interfering nucleic acid (siNA) molecule for reducing off-target effects. Provided are suitable modified siNAs, compositions and methods for producing respective siNAs, as well as kits comprising respective siNAs.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: August 23, 2016
    Assignee: QIAGEN GMBH
    Inventors: Peter Hahn, Eric Lader, Wolfgang Bielke, Alexander Azzawi, Jie Kang
  • Patent number: 9422556
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: August 23, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • Patent number: 9222090
    Abstract: The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 29, 2015
    Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY LIMITED
    Inventors: Tong Cheng, Tao Zhang, Yali Zhang, Ji Miao, Jun Zhang, Ningshao Xia
  • Patent number: 9200261
    Abstract: This disclosure relates to the isolation and sequencing of nucleic acid molecules that encode cytochrome P450 polypeptides from a Papaver somniferum cultivar; uses in the production of noscapine and identification of poppy cultivars that include genes that comprise said nucleic acid molecules.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: December 1, 2015
    Assignee: GlaxoSmithKline Australia Pty Limited
    Inventors: Thilo Winzer, Tracy Carol Walker, Ian Alexander Graham
  • Patent number: 9198983
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Mylip/Idol gene, and methods of using such dsRNA compositions to inhibit expression of Mylip/Idol.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: December 1, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Muthiah Manoharan
  • Patent number: 9193973
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Alynylam Pharmaceuticals, Inc., Dana-Farber Cancer Institute
    Inventors: William G. Kaelin, Jr., Victor Kotelianski, William Querbes, Brian Bettencourt
  • Patent number: 9175290
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: November 3, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • Patent number: 9175291
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: November 3, 2015
    Assignee: ISIS Pharmaceuticals Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Brett Monia
  • Patent number: 9150623
    Abstract: Disclosed is an isolated nucleic acid molecule comprising a nucleotide sequence that is at least 90% identical to a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO 4, wherein the protein has an aspartic acid (Asp) at amino acid position 106 Transgenic plants comp?sing the nucleic acid have reduced or delayed softening and detenoration of fruit compared to wild-type plants Methods of genetic screening for plants having reduced or delayed softening and detenoration of fruit, isolated oligonucleotides, and a method of imparting to a plant the dfd trait are also disclosed.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: October 6, 2015
    Assignees: Cornell Research Foundation, Inc., Boyce Thompson Institute for Plant Research
    Inventors: Jocelyn Kenneth Rose, Tal Isaacson-Lustig, Julia Vrebalov
  • Patent number: 9127275
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the KLF1 gene and the BCL11A gene, and methods of using such dsRNA compositions to inhibit expression of KLF1 and BCL11 A, respectively.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: September 8, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tatiana Novobrantseva, Brian Bettencourt, Stuart Milstein, Anna Borodovsky
  • Patent number: 9029636
    Abstract: This disclosure provides purified nucleic acids and polypeptides. Also provided are transgenic plants, seeds, and plant cells containing DNA for expression of the proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants, methods of making such plants and methods of making agricultural commodity including seeds and hybrid seeds from such plants.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: May 12, 2015
    Assignee: Monsanto Technology LLC
    Inventors: Wei Wu, Jack Tabaska, David Kovalic, Bo-Xing Qiu, Liang Guo
  • Publication number: 20150121572
    Abstract: Transgenic plants that have enhanced yield-related traits, such as increased seed oil production, are produced by genetically engineering the plants to down-regulate the expression of at least one BPM protein. Such transgenic plants can, for example, be cultivated and yield higher seed oil production than control plants which have not been genetically engineered for down regulation of a BPM protein.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 30, 2015
    Inventor: Hanjo Hellmann
  • Publication number: 20150121571
    Abstract: The present invention relates to a composition for improving a tolerance to a salt stress or a drought stress of a plant, and a method for preparing transformed plant exhibiting improved tolerance to salt stress or drought stress. The nucleotide sequences of the present invention are involved in salt or drought stress-tolerance, therefore may be effectively used for cultivating the plants with novel functional features which are less affected by climates and environments of the cultivated areas.
    Type: Application
    Filed: July 10, 2014
    Publication date: April 30, 2015
    Inventors: Woo Taek KIM, Jae Hwan HWANG, Dong Hye SEO
  • Publication number: 20150121570
    Abstract: The present invention relates to a composition for improving a tolerance to drought and oxidative stress of a plant, a plant transformed with the composition, a method for preparing a plant transformed with the composition, a method for improving a tolerance to a drought and oxidative stress and a composition and method for a germination rate of a plant. The nucleotide sequences of the present invention are involved in the drought and oxidative stress-tolerance and germination capacity, therefore may be effectively used for cultivating the plants with enhanced tolerance against abiotic stress or novel function of rapid growing or bolting.
    Type: Application
    Filed: April 22, 2014
    Publication date: April 30, 2015
    Applicant: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Woo Taek KIM, Eun Yu KIM, Moon Yong RYU, Yoon A CHOI
  • Publication number: 20150113684
    Abstract: The purpose of the invention is to identify a short-culm gene other than the sd1 gene and produce a short-culmed gramineous plant by utilizing a short-culm gene other than the sd1 gene. The present invention provides a method for producing a short-culmed gramineous plant utilizing gene d60 for shortening the culm of a gramineous plant, wherein the method for producing a short-culmed gramineous plant is characterized in that the expression of Os02g0280200 is suppressed. The present invention also provides a short-culmed gramineous plant and the like in which the expression of Os02g0280200 is suppressed.
    Type: Application
    Filed: March 7, 2013
    Publication date: April 23, 2015
    Inventor: Motonori Tomita
  • Patent number: 9012723
    Abstract: This disclosure provides purified nucleic acids and polypeptides. Also provided are transgenic plants, seeds, and plant cells containing DNA for expression of the proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants, methods of making such plants and methods of making agricultural commodity including seeds and hybrid seeds from such plants.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: April 21, 2015
    Assignee: Monsanto Technology LLC
    Inventors: Liang Guo, David K. Kovalic, Bo-Xing Qiu, Jack E. Tabaska, Wei Wu
  • Patent number: 9000264
    Abstract: The present invention provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: April 7, 2015
    Assignee: Monsanto Technology LLC
    Inventors: Edwards M. Allen, Larry A. Gilbertson, Nancy M. Houmard, Shihshieh Huang, Elysia K. Krieger, Thomas M. Malvar
  • Publication number: 20150096079
    Abstract: A method of introducing naked dsRNA into a seed is provided. The method comprising contacting the seed with the naked dsRNA under conditions which allow penetration of the dsRNA into the seed, thereby introducing the dsRNA into the seed.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 2, 2015
    Applicant: A.B. Seeds Ltd.
    Inventors: Amir Avniel, Efrat Lidor-Nili, Rudy Maor, Ofir Meir, Orly Noivirt-Brik, Osnat Yanai-Azulay
  • Patent number: 8993842
    Abstract: Methods and means for producing xylan structures in plants having a non-native saccharide moiety substitution side chain component, plants and plant cells comprising modified xylan structures, methods of identifying mutant plants comprising xylan structures in plants having a non-native saccharide moiety substitution pattern side chain component, uses thereof, and isolated xylan structures and uses thereof.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: March 31, 2015
    Assignee: Cambridge Enterprise Limited
    Inventors: Paul Dupree, Godfrey Preston Miles
  • Patent number: 8993843
    Abstract: The present application provides methods and compositions that modulate fruit dehiscence in plants.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of California
    Inventors: Martin F. Yanofsky, Sarah Liljegren
  • Publication number: 20150089688
    Abstract: Compositions and methods for inducing gene silencing events in plants are disclosed. The compositions typical include a polynucleotide encoding an miRNA target sequence operably linked to a sequence of from a target gene, cDNA or mRNA, or fragment thereof. When expressed in the presence of an miRNA specific for the miRNA target sequence the compositions can induce production of trans-acting siRNA that silence the target of interest. Transgenic plants and preferred plant pathways that can be targeted using the disclosed methods and compositions are also disclosed.
    Type: Application
    Filed: December 3, 2014
    Publication date: March 26, 2015
    Inventors: Thomas B. Jacobs, Wayne A. Parrott, Lila O. Vodkin
  • Patent number: 8987556
    Abstract: The present invention provides isolated polynucleotide sequences encoding ?-D-N-acetylhexosaminidase. The present invention further provides DNA construct comprising the polynucleotide sequence coding for ?-D-N-acetylhexosaminidase in sense or antisense orientation, RNAi construct, recombinant vector comprising the construct and host cells comprising the recombinant vector disclosed in the present invention. The present invention further provides transgenic plant, plant cell, transgenic progeny and seeds expressing the polynucleotide with reduced ?-D-N-acetylhexosaminidase protein accumulation, having enhanced fruit shelf life.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: March 24, 2015
    Assignee: National Institute of Plant Genome Research
    Inventors: Asis Datta, Subhra Chakraborty, Niranjan Chakraborty, Vijaykumar Meli Siddesh, Sumit Ghosh
  • Patent number: 8987553
    Abstract: The invention provides methods for improving plant yield, particularly under nitrogen limiting conditions. According to the invention, applicants have discovered that modulating ACC synthase activity in plants improves yield of plants, even when grown under low nitrogen conditions. The same plants, while demonstrating improved yield over non-modified plants, exhibited no deleterious effects under normal nitrogen conditions. The invention further provides methods using recombinant expression cassettes, host cells and transgenic plants.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: March 24, 2015
    Assignee: Pioneer Hi Bred International Inc
    Inventors: Nicholas J. Bate, Sarah T. Collinson, Jeffrey E. Habben, Honor Renee Lafitte, Kellie Reimann